YOLT-204
/ YolTech Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 25, 2025
YOLT-204 in Patients With Hemoglobinopathies
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Guangzhou Women and Children's Medical Center
New P1 trial • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease
January 20, 2025
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
(PRNewswire)
- "YolTech Therapeutics...announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT)....The clinical trial for YOLT-204 is a dose-escalation study to preliminarily examine the safety and efficacy of a single-dose regimen with YOLT-204 in TDT. If successful, YOLT-204 may eventually provide an off-the-shelf curative treatment for TDT patients without conditioning chemotherapy and HSCT (Hematopoietic Stem Cell Transplantation)."
Trial status • Beta-Thalassemia
November 07, 2024
A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia
(clinicaltrials.gov)
- P1 | N=3 | Not yet recruiting | Sponsor: First Affiliated Hospital of Guangxi Medical University
New P1 trial • Beta-Thalassemia • Genetic Disorders
1 to 3
Of
3
Go to page
1